These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 30015676)
21. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197 [TBL] [Abstract][Full Text] [Related]
22. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Potkin SG; Preda A Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352 [TBL] [Abstract][Full Text] [Related]
23. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558 [TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566 [TBL] [Abstract][Full Text] [Related]
26. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Wang Y; Wang X; Harlin M; Larsen F; Panni M; Yildirim M; Madera J; Arias L; Forbes A; Mustafa N; Ruiz-White I; Raoufinia A Curr Med Res Opin; 2021 Nov; 37(11):1961-1972. PubMed ID: 34407720 [TBL] [Abstract][Full Text] [Related]
27. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil. Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338 [TBL] [Abstract][Full Text] [Related]
28. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Fleischhacker WW; Sanchez R; Johnson B; Jin N; Forbes RA; McQuade R; Baker RA; Carson W; Kane JM Int Clin Psychopharmacol; 2013 Jul; 28(4):171-6. PubMed ID: 23615694 [TBL] [Abstract][Full Text] [Related]
29. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204 [TBL] [Abstract][Full Text] [Related]
30. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082 [TBL] [Abstract][Full Text] [Related]
31. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique. Farwick S; Hickey MB; Jacobs G; Faldu SP; Vandiver J; Weiden PJ J Psychiatr Pract; 2019 Mar; 25(2):82-90. PubMed ID: 30849056 [TBL] [Abstract][Full Text] [Related]
32. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253 [TBL] [Abstract][Full Text] [Related]
34. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202 [TBL] [Abstract][Full Text] [Related]
35. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595 [TBL] [Abstract][Full Text] [Related]
37. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Potkin SG; Risinger R; Du Y; Zummo J; Bose A; Silverman B; Stankovic S; Ehrich E Schizophr Res; 2017 Dec; 190():115-120. PubMed ID: 28342578 [TBL] [Abstract][Full Text] [Related]